Feeds:
Posts
Comments

Archive for the ‘Biopsy’ Category

NEW PROSTATE CANCER INFO-LINK: Transperineal, template-guided mapping biopsies can find prostate cancer where more traditional 8- or 12-core transrectal ultrasound (TRUS)-guided biopsies often don’t, new research confirms – but is this really an advantage? READ MORE>

Read Full Post »

URO TODAY: Dutch medical scientists have worked out a way to use various medical information – including PSA level – to accurately calculate whether a man needs repeated biopsies for suspected prostate cancer. READ MORE>

An individualized screening algorithm using other available pre-biopsy information in addition to PSA level can result in a considerable reduction of unnecessary biopsies. Very few important prostate cancer cases – for which diagnosis at a subsequent screening visit might be too late for treatment with curative intent – would be missed.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: A new study appears to confirm that transperineal three-dimensional prostate mapping biopsies can be used with a high level of safety to accurately stage appropriately selected prostate cancer patients. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK:  A new way to test negative biopsy samples to see if in fact prostate cancer is present will be tested on 500 US volunteers. READ MORE>

Gen-Probe announced yesterday that it has begun a clinical trial designed to seek U.S. regulatory approval of the PROGENSA® PCA3 assay. Gen-Probe to market their PCA3 test only for the evaluation of prostate cancer risk in patients who had had at least one negative biopsy.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Interpretation of biopsy sample slides by pathologists has played a significant role in a Gleason score “shift” over the past 15 years, according to a new study. However, there are some questions over some of the researchers’ conclusions. READ MORE>

Read Full Post »

URO TODAY: Researchers have developed an accurate tool to determine the chances of finding prostate cancer in men who have already had a negative biopsy and for whom a repeat biopsy is being considered. READ MORE>

Read Full Post »

URO TODAY: The UK National Institute for Health and Clinical Excellence guidance recommends conservative management of men with ‘low-risk’ localised prostate cancer, monitoring the disease using changes to PSA over time and re-biopsy. However, there is little evidence of the changes in PSA level that should alert to the need for clinical re-assessment. READ MORE> and HERE> (New Prostate Cancer Infolink)

Read Full Post »

« Newer Posts - Older Posts »